Loading stock data…
$18.56-0.29 (-1.54%)
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
GH Research PLC in the Healthcare sector is trading at $18.56 with a market capitalization of $1.9B. Wall Street consensus targets $42.89 (9 analysts), implying a +131.1% move over the next 12 months. The stock is currently 41% below its 52-week high of $31.44, remaining 12.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.45M↓ | -$18.75M↓ | -$16.70M↓ | -$16.54M↓ | -$14.69M |
| Net Income | -$15.15M↑ | -$18.97M↓ | -$14.14M↓ | -$14.02M↓ | -$9.29M |
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate...